Immunohistochemical Study of HER2 and TUBB3 Proteins in Extramammary Paget Disease
- 1 August 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Dermatopathology
- Vol. 32 (6), 578-585
- https://doi.org/10.1097/dad.0b013e3181cd35e0
Abstract
Metastatic extramammary Paget disease (EMPD) is a potentially fatal malignancy for which effective chemotherapy and good biomarkers are desirable for management. We investigated the status of human epidermal growth factor receptor (HER2) and neuronal β-tubulin isotype (class III β-tubulin; TUBB3), whose overexpression is a factor involved in resistance of tumor cells to taxane derivatives) in 32 patients with EMPD. HER2 status was evaluated by immunohistochemistry followed by fluorescence in situ hybridization, and TUBB3 status was evaluated by immunohistochemistry. On the basis of the US Food and Drug Administration-approved criteria, 20 (63%) of the 32 EMPD tumors were found to overexpress HER2. Positive immunoreactivity for TUBB3 was observed in 7 (22%) of the 32 patients. Although some clinicopathologic variables (nodule formation, depth of tumor cells, presence of lymph node metastasis, and serum carcinoembryonic antigen level) were significantly associated with disease outcome (P < 0.05), HER2 gain or aberrant TUBB3 expression showed no significant correlation. However, the higher incidence of HER2 gain and the relatively lower incidence of aberrant TUBB3 expression suggested that HER2-targeted immunotherapy combined with taxane derivatives is warranted for metastatic EMPD, and that HER2 and TUBB3 status might be a good biomarker for determining the most appropriate therapeutic modality.Keywords
This publication has 34 references indexed in Scilit:
- Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget’s diseaseBritish Journal of Dermatology, 2009
- Metastatic extramammary Paget’s disease treated with paclitaxel and trastuzumab combination chemotherapyThe Journal of Dermatology, 2009
- Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancerNature Clinical Practice Oncology, 2008
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840Journal of Clinical Oncology, 2008
- Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same RegimenClinical Cancer Research, 2007
- Metastatic extramammary Paget's disease successfully controlled with tumour dormancy therapy using docetaxelBritish Journal of Dermatology, 2005
- Extramammary Paget's diseaseBJOG: An International Journal of Obstetrics and Gynaecology, 2005
- Docetaxel Induced Durable Response in Advanced Extramammary Paget's Disease: A Case ReportThe Journal of Dermatology, 2002
- Cytoreductive combination chemotherapy for regionally advanced unresectable extramammary Paget carcinomaCancer, 1992
- Perianal Paget's diseaseDiseases of the Colon & Rectum, 1990